251 related articles for article (PubMed ID: 28396541)
1. Antibiotic Resistance Markers in Burkholderia pseudomallei Strain Bp1651 Identified by Genome Sequence Analysis.
Bugrysheva JV; Sue D; Gee JE; Elrod MG; Hoffmaster AR; Randall LB; Chirakul S; Tuanyok A; Schweizer HP; Weigel LM
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28396541
[No Abstract] [Full Text] [Related]
2. Mechanisms of Resistance to Folate Pathway Inhibitors in
Podnecky NL; Rhodes KA; Mima T; Drew HR; Chirakul S; Wuthiekanun V; Schupp JM; Sarovich DS; Currie BJ; Keim P; Schweizer HP
mBio; 2017 Sep; 8(5):. PubMed ID: 28874476
[TBL] [Abstract][Full Text] [Related]
3. Burkholderia pseudomallei class a beta-lactamase mutations that confer selective resistance against ceftazidime or clavulanic acid inhibition.
Tribuddharat C; Moore RA; Baker P; Woods DE
Antimicrob Agents Chemother; 2003 Jul; 47(7):2082-7. PubMed ID: 12821450
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional and post-transcriptional regulation of PenA β-lactamase in acquired Burkholderia pseudomallei β-lactam resistance.
Chirakul S; Norris MH; Pagdepanichkit S; Somprasong N; Randall LB; Shirley JF; Borlee BR; Lomovskaya O; Tuanyok A; Schweizer HP
Sci Rep; 2018 Jul; 8(1):10652. PubMed ID: 30006637
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of bla(PenA) and bla(OXA) in Burkholderia pseudomallei Isolated from Patients at Sappasitthiprasong Hospital and Their Susceptibility to Ceftazidime and Carbapenems.
Panya M; Thirat S; Wanram S; Panomket P; Nilsakul J
J Med Assoc Thai; 2016 Jan; 99 Suppl 1():S12-6. PubMed ID: 26817233
[TBL] [Abstract][Full Text] [Related]
6. Antimicrobial susceptibility and genetic characterisation of Burkholderia pseudomallei isolated from Malaysian patients.
Khosravi Y; Vellasamy KM; Mariappan V; Ng SL; Vadivelu J
ScientificWorldJournal; 2014; 2014():132971. PubMed ID: 25379514
[TBL] [Abstract][Full Text] [Related]
7. Optical microscopy reveals the dynamic nature of B. pseudomallei morphology during β-lactam antimicrobial susceptibility testing.
McLaughlin HP; Bugrysheva J; Sue D
BMC Microbiol; 2020 Jul; 20(1):209. PubMed ID: 32677888
[TBL] [Abstract][Full Text] [Related]
8. Variations in ceftazidime and amoxicillin-clavulanate susceptibilities within a clonal infection of Burkholderia pseudomallei.
Sam IC; See KH; Puthucheary SD
J Clin Microbiol; 2009 May; 47(5):1556-8. PubMed ID: 19297597
[TBL] [Abstract][Full Text] [Related]
9. In vitro activities of amoxicillin-clavulanate, doxycycline, ceftazidime, imipenem, and trimethoprim-sulfamethoxazole against biofilm of Brazilian strains of Burkholderia pseudomallei.
Bandeira Tde J; Moreira CA; Brilhante RS; Castelo-Branco Dde S; Neto MP; Cordeiro Rde A; Rodrigues Tde J; Rocha MF; Sidrim JJ
Antimicrob Agents Chemother; 2013 Nov; 57(11):5771-3. PubMed ID: 24002089
[TBL] [Abstract][Full Text] [Related]
10. Antibiotic susceptibility of Burkholderia pseudomallei from tropical northern Australia and implications for therapy of melioidosis.
Jenney AW; Lum G; Fisher DA; Currie BJ
Int J Antimicrob Agents; 2001 Feb; 17(2):109-13. PubMed ID: 11165114
[TBL] [Abstract][Full Text] [Related]
11. Burkholderia ubonensis Meropenem Resistance: Insights into Distinct Properties of Class A β-Lactamases in Burkholderia cepacia Complex and Burkholderia pseudomallei Complex Bacteria.
Somprasong N; Hall CM; Webb JR; Sahl JW; Wagner DM; Keim P; Currie BJ; Schweizer HP
mBio; 2020 Apr; 11(2):. PubMed ID: 32291300
[No Abstract] [Full Text] [Related]
12. Characterization of ceftazidime resistance mechanisms in clinical isolates of Burkholderia pseudomallei from Australia.
Sarovich DS; Price EP; Von Schulze AT; Cook JM; Mayo M; Watson LM; Richardson L; Seymour ML; Tuanyok A; Engelthaler DM; Pearson T; Peacock SJ; Currie BJ; Keim P; Wagner DM
PLoS One; 2012; 7(2):e30789. PubMed ID: 22363490
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial Susceptibility of Western Hemisphere Isolates of
Bugrysheva JV; Lascols C; McLaughlin HP; Gee JE; Elrod MG; Sue D
Microb Drug Resist; 2021 Sep; 27(9):1176-1185. PubMed ID: 33570476
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of antibiotic resistance in Burkholderia pseudomallei: implications for treatment of melioidosis.
Schweizer HP
Future Microbiol; 2012 Dec; 7(12):1389-99. PubMed ID: 23231488
[TBL] [Abstract][Full Text] [Related]
15. Burkholderia pseudomallei acquired ceftazidime resistance due to gene duplication and amplification.
Chirakul S; Somprasong N; Norris MH; Wuthiekanun V; Chantratita N; Tuanyok A; Schweizer HP
Int J Antimicrob Agents; 2019 May; 53(5):582-588. PubMed ID: 30639528
[TBL] [Abstract][Full Text] [Related]
16. In-vitro activity of β-lactams/trimethoprim-sulfamethoxazole combinations against different strains of Burkholderia pseudomallei.
Mohamad NI; Harun A; Hasan H; Deris ZZ
Trop Biomed; 2022 Mar; 39(1):11-16. PubMed ID: 35225295
[TBL] [Abstract][Full Text] [Related]
17. The BpeEF-OprC efflux pump is responsible for widespread trimethoprim resistance in clinical and environmental Burkholderia pseudomallei isolates.
Podnecky NL; Wuthiekanun V; Peacock SJ; Schweizer HP
Antimicrob Agents Chemother; 2013 Sep; 57(9):4381-6. PubMed ID: 23817379
[TBL] [Abstract][Full Text] [Related]
18. Burkholderia pseudomallei resistance to antibiotics in biofilm-induced conditions is related to efflux pumps.
Sirijant N; Sermswan RW; Wongratanacheewin S
J Med Microbiol; 2016 Nov; 65(11):1296-1306. PubMed ID: 27702426
[TBL] [Abstract][Full Text] [Related]
19. Antibiotic resistance in Burkholderia species.
Rhodes KA; Schweizer HP
Drug Resist Updat; 2016 Sep; 28():82-90. PubMed ID: 27620956
[TBL] [Abstract][Full Text] [Related]
20. Genomic and RT-qPCR analysis of trimethoprim-sulfamethoxazole and meropenem resistance in Burkholderia pseudomallei clinical isolates.
Schnetterle M; Gorgé O; Nolent F; Boughammoura A; Sarilar V; Vigier C; Guillier S; Koch L; Degand N; Ramisse V; Tichadou X; Girleanu M; Favier AL; Valade E; Biot F; Neulat-Ripoll F
PLoS Negl Trop Dis; 2021 Feb; 15(2):e0008913. PubMed ID: 33592059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
